New CSF Biomarkers for Alzheimer's Disease
About this study
Today, the Alzheimer's disease (AD) diagnosis is founded not only on clinical criteria but also on complementary examinations to confirm a physiopathological process of AD. In complex cases, lumbar punction could be necessary in order to measure Aβ peptides and Total and phosphorylated Tau but new biomarkers could be useful. The main objective of this project is to conserve these cerebrospinal fluids, collected in usual practice in order to validate new biomarkers for diagnosis, prognosis or therapeutic following of Alzheimer's disease and other dementia.
- Condition
- Alzheimer Disease, Dementia, Neurodegenerative Diseases
- Sponsor
- Central Hospital, Nancy, France
Who can join
- Age
- Not specified
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 2
- Study condition: Alzheimer Disease, Dementia, Neurodegenerative Diseases
- Lumbar punction collected in usual practice in the context of dementia diagnosis
Exclusion 1
- Absence of consent
Where
1 site, 1 recruiting
CHRU De Nancy
Nancy, Grand Est, France
Potential match only. Final eligibility is determined by the study team.